Congratulations to everyone who took part and for a fantastic and insightful conference from UKSPA, The United Kingdom Science Park Association.
Dr Sally Ann Forsyth OBE, CEO of SBC, said:
“Stevenage Bioscience Catalyst is truly honoured to win Most Successful Science Park (Small) Award, and for the SBC graduate Autolus Therapeutics to have won Most Successful Company, nominated by SBC as an UKSPA partner.
With some fierce competition in the mix, we’re delighted to have been recognised for our dedication to creating the best environment for companies to start-up and scale-up to deliver health innovations improving the quality of people’s lives.”
Since SBC opened in 2012:
- Over 110 health innovation business have been based on the campus
- Companies at SBC have raised more than £3.6 billion in funding
- There have been 7 exits at SBC, totalling +£300 million in valuation on average per company in 8 years
- Autolus Therapeutics, a spin-out from UCL (2014) manufacturing (CAR) T-cell therapies for cancer treatment, is one of SBC’s most successful exits.
- In less than ten years, the business has more than doubled its presence in Hertfordshire going from 45 staff to +300 in its newly built location in Stevenage town centre.
- Its total group portfolio is now valued at £955m.
*Source: Beauhurst, based on data sourced by Hertfordshire LEP, March 2021.
